Strong GLP pedigree Eurofins Advinus brings 30+ years of GLP experience and a track record of 90+ INDs and 25,000+ regulatory studies, indicating reliability for late-stage preclinical and regulatory submission support. Target biopharma customers seeking compliant, well-documented CRO/CDMO partnerships can be prioritized.

Full service scope From medicinal chemistry and ADMET/DMPK to CMC, toxicology, bioanalytical development and GMP manufacturing, the integrated suite enables end-to-end outsourcing. Sales opportunities exist with companies looking to minimize vendor handoffs and consolidate CRO/CDMO relationships.

Global regulatory readiness In-house expertise aligned with USFDA and EMA guidelines and extensive regulatory study history position Advinus as a strong partner for NDA/IND submissions and biosimilar developments. Focus on clients aiming for accelerated regulatory timelines and compliant data packages.

Scaleable manufacturing Capabilities to support multi-kilogram to multi-ton scale for preclinical to commercial manufacturing, including RSMs and NCEs, suggest opportunities with sponsors planning scale-up, process development, and seamless transition from discovery to market.

Strategic partnerships Historical collaboration with major groups (Tata, Eurofins, GRMA) and industry players indicates a network-ready for co-development, accelerated programs, and multi-site partnerships. Target customers seeking established alliance credibility and cross-border execution should be engaged.